[J01EC02, sulfadiazine, Methenamine can cause a decrease in the absorption of Sulfadiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01ED07, sulfamerazine, Methenamine can cause a decrease in the absorption of Sulfamerazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AB01, sulfamethizole, Methenamine can cause a decrease in the absorption of Sulfamethizole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EC01, sulfamethoxazole, Methenamine can cause a decrease in the absorption of Sulfamethoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01ED05, sulfamethoxypyridazine, Methenamine can cause a decrease in the absorption of Sulfamethoxypyridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AB02, sulfisoxazole, Methenamine can cause a decrease in the absorption of Sulfisoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Tetracaine.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Trichlormethiazide.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Methenamine is combined with Warfarin.]
[A02BC04, rabeprazole, The therapeutic efficacy of Methenamine can be decreased when used in combination with Rabeprazole.]
[A02AA05, magnesium silicate, The therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium silicate.]
[A02AC02, calcium silicate, The therapeutic efficacy of Methenamine can be decreased when used in combination with Calcium silicate.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Bendroflumethiazide.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Benzocaine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Benzyl alcohol.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Methenamine is combined with Acenocoumarol.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Methenamine is combined with Dicoumarol.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Methenamine is combined with Tioclomarol.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium peroxide.]
[S01EC01, acetazolamide, The serum concentration of the active metabolites of Methenamine can be reduced when Methenamine is used in combination with Acetazolamide resulting in a loss in efficacy.]
[A02BC03, lansoprazole, The therapeutic efficacy of Methenamine can be decreased when used in combination with Lansoprazole.]
[A02AB06, aloglutamol, The therapeutic efficacy of Methenamine can be decreased when used in combination with Aloglutamol.]
[A02AD05, aluminum magnesium silicate, The therapeutic efficacy of Methenamine can be decreased when used in combination with Almasilate.]
[A02AB03, aluminum phosphate, The therapeutic efficacy of Methenamine can be decreased when used in combination with Aluminium phosphate.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Bupivacaine.]
[M02AA03, clofezone, The therapeutic efficacy of Methenamine can be decreased when used in combination with Rabeprazole.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Oxybuprocaine.]
[A12AA04, calcium carbonate, The therapeutic efficacy of Methenamine can be decreased when used in combination with Calcium carbonate.]
[A02BX12, bismuth subnitrate, The therapeutic efficacy of Methenamine can be decreased when used in combination with Bismuth subnitrate.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Capsaicin.]
[V03AE10, sodium zirconium cyclosilicate, The therapeutic efficacy of Methenamine can be decreased when used in combination with Sodium zirconium cyclosilicate.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Chloroprocaine.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Cyclothiazide.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Dyclonine.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Chlorothiazide.]
[A10BB02, chlorpropamide, Methenamine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[A02BA01, cimetidine, The therapeutic efficacy of Methenamine can be decreased when used in combination with Cimetidine.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Levobupivacaine.]
[A02BC08, vonoprazan, The therapeutic efficacy of Methenamine can be decreased when used in combination with Vonoprazan.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Cocaine.]
[A02AD04, hydrotalcite, The therapeutic efficacy of Methenamine can be decreased when used in combination with Hydrotalcite.]
[A02BC05, esomeprazole, The therapeutic efficacy of Methenamine can be decreased when used in combination with Esomeprazole.]
[A02AD02, magaldrate, The therapeutic efficacy of Methenamine can be decreased when used in combination with Magaldrate.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium carbonate.]
[R03CB02, methoxyphenamine, The serum concentration of Methoxyphenamine can be decreased when it is combined with Methenamine.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Cyclopenthiazide.]
[M03AC11, cisatracurium, Methenamine may increase the neuromuscular blocking activities of Cisatracurium.]
[N06BA02, dextroamphetamine, The serum concentration of Amphetamine can be decreased when it is combined with Methenamine.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Cinchocaine.]
[S01EC02, dichlorphenamide, The serum concentration of the active metabolites of Methenamine can be reduced when Methenamine is used in combination with Diclofenamide resulting in a loss in efficacy.]
[A08AA03, diethylpropion, The serum concentration of Diethylpropion can be decreased when it is combined with Methenamine.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Pramocaine.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Diphenhydramine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Ropivacaine.]
[N03AX15, zonisamide, The serum concentration of the active metabolites of Methenamine can be reduced when Methenamine is used in combination with Zonisamide resulting in a loss in efficacy.]
[A02BC02, pantoprazole, The therapeutic efficacy of Methenamine can be decreased when used in combination with Pantoprazole.]
[C01CA15, gepefrine, The serum concentration of Gepefrine can be decreased when it is combined with Methenamine.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Etidocaine.]
[A02BA04, nizatidine, The therapeutic efficacy of Methenamine can be decreased when used in combination with Nizatidine.]
[A02BA03, famotidine, The therapeutic efficacy of Methenamine can be decreased when used in combination with Famotidine.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Methenamine is combined with Fluindione.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Hydroflumethiazide.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Articaine.]
[A02AB01, aluminum hydroxide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Aluminum hydroxide.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Methenamine.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Lidocaine.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium oxide.]
[C02BB01, mecamylamine, Methenamine may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA11, mephentermine, The serum concentration of Mephentermine can be decreased when it is combined with Methenamine.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Mepivacaine.]
[N06BA03, methamphetamine, The serum concentration of Metamfetamine can be decreased when it is combined with Methenamine.]
[A03AB07, methantheline, The therapeutic efficacy of Methenamine can be decreased when used in combination with Methantheline.]
[S01EC05, methazolamide, The serum concentration of the active metabolites of Methenamine can be reduced when Methenamine is used in combination with Methazolamide resulting in a loss in efficacy.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Methyclothiazide.]
[N06BA12, lisdexamfetamine, The serum concentration of Lisdexamfetamine can be decreased when it is combined with Methenamine.]
[N06BA01, amphetamine, The serum concentration of Amphetamine can be decreased when it is combined with Methenamine.]
[A02BC01, omeprazole, The therapeutic efficacy of Methenamine can be decreased when used in combination with Omeprazole.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Methenamine is combined with Phenindione.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Methenamine is combined with Phenprocoumon.]
[A08AA01, phentermine, The serum concentration of Phentermine can be decreased when it is combined with Methenamine.]
[A02BC06, dexlansoprazole, The therapeutic efficacy of Methenamine can be decreased when used in combination with Dexlansoprazole.]
[C03AA05, polythiazide, The therapeutic efficacy of Methenamine can be decreased when used in combination with Polythiazide.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Prilocaine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Procaine.]
[R01BA02, pseudoephedrine, The serum concentration of Pseudoephedrine can be decreased when it is combined with Methenamine.]
[A02BA02, ranitidine, The therapeutic efficacy of Methenamine can be decreased when used in combination with Ranitidine.]
